دورية أكاديمية
Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.
| العنوان: | Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy. |
|---|---|
| المؤلفون: | Magbanua MJM; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California., Ahmed Z; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California., Sayaman RW; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California., Brown Swigart L; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California., Hirst GL; Department of Surgery, University of California San Francisco, San Francisco, California., Yau C; Department of Surgery, University of California San Francisco, San Francisco, California., Wolf DM; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California., Li W; Department of Radiology, University of California San Francisco, San Francisco, California., Delson AL; Breast Science Advocacy Core, University of California San Francisco, San Francisco, California., Perlmutter J; Breast Science Advocacy Core, University of California San Francisco, San Francisco, California., Pohlmann P; Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Symmans WF; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas., Yee D; Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota., Hylton NM; Department of Radiology, University of California San Francisco, San Francisco, California., Esserman LJ; Department of Surgery, University of California San Francisco, San Francisco, California., DeMichele AM; Division of Hematology/Oncology, University of Pennsylvania, Philadelphia, Pennsylvania., Rugo HS; Division of Hematology/Oncology, University of California San Francisco, San Francisco, California., van 't Veer LJ; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California. |
| المصدر: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Jun 03; Vol. 30 (11), pp. 2444-2451. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Denville, NJ : American Association for Cancer Research, c1995- |
| مواضيع طبية MeSH: | Biomarkers, Tumor*/blood , Breast Neoplasms*/blood , Breast Neoplasms*/diagnosis , Breast Neoplasms*/drug therapy , Cell-Free Nucleic Acids*/blood , Neoadjuvant Therapy* , Neoplasm Recurrence, Local*/blood , Neoplasm Recurrence, Local*/diagnosis , Neoplasm Recurrence, Local*/drug therapy, Adult ; Aged ; Female ; Humans ; Middle Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Circulating Tumor DNA/blood ; Circulating Tumor DNA/genetics ; Prognosis ; Receptor, ErbB-2/metabolism ; Receptor, ErbB-2/genetics ; Treatment Outcome ; Triple Negative Breast Neoplasms/drug therapy ; Triple Negative Breast Neoplasms/pathology ; Triple Negative Breast Neoplasms/blood ; Triple Negative Breast Neoplasms/mortality ; Triple Negative Breast Neoplasms/genetics |
| مستخلص: | Purpose: We previously demonstrated the clinical significance of circulating tumor DNA (ctDNA) in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy (NAC). Here, we compared its predictive and prognostic value with cell-free DNA (cfDNA) concentration measured in the same samples from the same patients. Experimental Design: 145 patients with hormone receptor (HR)-positive/HER2-negative and 138 triple-negative breast cancer (TNBC) with ctDNA data from a previous study were included in the analysis. Associations of serial cfDNA concentration with residual cancer burden (RCB) and distant recurrence-free survival (DRFS) were examined. Results: In TNBC, we observed a modest negative correlation between cfDNA concentration 3 weeks after treatment initiation and RCB, but none of the other timepoints showed significant correlation. In contrast, ctDNA was significantly positively correlated with RCB at all timepoints (all R > 0.3 and P < 0.05). In the HR-positive/HER2-negative group, cfDNA concentration did not associate with response to NAC, but survival analysis showed that high cfDNA shedders at pretreatment had a significantly worse DRFS than low shedders (hazard ratio, 2.12; P = 0.037). In TNBC, the difference in survival between high versus low cfDNA shedders at all timepoints was not statistically significant. In contrast, as previously reported, ctDNA at all timepoints was significantly correlated with DRFS in both subtypes. Conclusions: In TNBC, cfDNA concentrations during therapy were not strongly correlated with response or prognosis. In the HR-positive/HER2-negative group, pretreatment cfDNA concentration was prognostic for DRFS. Overall, the predictive and prognostic value of cfDNA concentration was more limited than that of ctDNA. (©2024 American Association for Cancer Research.) |
| References: | Breast Cancer Res. 2019 Dec 19;21(1):149. (PMID: 31856868) Cancer Discov. 2023 Oct 5;13(10):2166-2179. (PMID: 37565753) Cancer Treat Rev. 2022 Mar;104:102362. (PMID: 35219090) Int J Cancer. 2021 Apr 1;148(7):1665-1675. (PMID: 33320961) Cell Rep. 2020 Jun 30;31(13):107830. (PMID: 32610131) Cancer Cell. 2019 Oct 14;36(4):350-368. (PMID: 31614115) Ann Oncol. 2021 Feb;32(2):229-239. (PMID: 33232761) Cancer Cell. 2023 Jun 12;41(6):1091-1102.e4. (PMID: 37146605) N Engl J Med. 2016 Jul 7;375(1):23-34. (PMID: 27406347) Mol Cancer. 2023 Jan 21;22(1):15. (PMID: 36681803) Sci Rep. 2020 Sep 3;10(1):14601. (PMID: 32884019) N Engl J Med. 2017 Nov 9;377(19):1836-1846. (PMID: 29117498) Expert Opin Biol Ther. 2012 Jun;12 Suppl 1:S209-15. (PMID: 22594497) NPJ Breast Cancer. 2021 Mar 25;7(1):32. (PMID: 33767190) JAMA Oncol. 2021 Nov 01;7(11):1654-1663. (PMID: 34529000) NPJ Breast Cancer. 2021 Mar 26;7(1):35. (PMID: 33772032) EBioMedicine. 2019 Nov;49:284-290. (PMID: 31648993) Surg Oncol. 2022 Jun;42:101753. (PMID: 35594723) JAMA Oncol. 2020 Sep 1;6(9):1355-1362. (PMID: 32701140) Cancers (Basel). 2020 Oct 24;12(11):. (PMID: 33114393) |
| معلومات مُعتمدة: | R01 CA255442 United States CA NCI NIH HHS; 28XS197 P-0518835 National Cancer Institute (NCI); K01 CA279498 United States CA NCI NIH HHS; R01CA255442 National Cancer Institute (NCI); PO1-CA210961 National Cancer Institute (NCI); P01 CA210961 United States CA NCI NIH HHS; U54 CA209891 United States CA NCI NIH HHS |
| المشرفين على المادة: | 0 (Biomarkers, Tumor) 0 (Cell-Free Nucleic Acids) 0 (Circulating Tumor DNA) EC 2.7.10.1 (ERBB2 protein, human) EC 2.7.10.1 (Receptor, ErbB-2) |
| تواريخ الأحداث: | Date Created: 20240312 Date Completed: 20240603 Latest Revision: 20240829 |
| رمز التحديث: | 20240830 |
| مُعرف محوري في PubMed: | PMC11147708 |
| DOI: | 10.1158/1078-0432.CCR-23-2928 |
| PMID: | 38470545 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1557-3265 |
|---|---|
| DOI: | 10.1158/1078-0432.CCR-23-2928 |